Acuerdo de asociación transpacífico: cuando la cura es peor que la enfermedad
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Solari, LelyIssue Date
2015-09Keywords
Acuerdos internacionalesNegociación
Sistemas de salud
International agreements
Negotiating
Health systems
xmlui.metadata.dc.contributor.email
[email protected]
Metadata
Show full item recordOther Titles
Transpacific partnership: when the cure is worse than the diseaseCitation
SOLARI, Lely. Acuerdo de asociación transpacífico: cuando la cura es peor que la enfermedad. Rev. perú. med. exp. salud publica [online]. 2015, vol.32, n.3, pp. 586-590. ISSN 1726-4634.Publisher
Instituto Nacional de Salud (INS)Journal
Revista peruana de medicina experimental y salud públicaPubMed ID
26580944Abstract
El Perú está negociando el Acuerdo de Asociación Transpacífico, un acuerdo comercial que podría tener serias implicancias para los sistemas de salud de las naciones incluidas. Los capítulos de transparencia y propiedad intelectual son los más controversiales. El primero porque abre la posibilidad a los grupos interesados a objetar las decisiones de las autoridades sanitarias acerca de la incorporación de tecnologías sanitarias al sistema de salud, dándoles mecanismos de arbitraje si sus productos no son incorporados al sistema. El segundo, porque plantea restricciones al ingreso de productos genéricos al ampliar el período de datos de prueba e implementar mecanismos de oposición al registro de los mismos. Adicionalmente, el acuerdo contempla la posibilidad de restringir la regulación del consumo de alcohol, tabaco y alimentos procesados. Se deben crear sistemas de vigilancia del impacto del acuerdo si este se concreta, y generar mecanismos que impidan que los escasos recursos disponibles para la salud se desvíen a financiar tecnología de punta que no necesariamente va a tener un impacto positivo a nivel poblacional.Peru is negotiating the Transpacific Partnership Agreement, a commercial treaty that could have deleterious implications for the health systems of the included partners. Transparency and Intellectual Property chapters are the most controversial elements. The first mostly because it opens the possibility for groups of interest to refuse decisions being taken by the sanitary authorities concerning the incorporation of health technologies to the public health systems. The second because it poses restrictions to the entrance of generic medical products, widening the period of data exclusivity and implementing mechanisms of opposition to their registry. Other chapters include strategies to block the states from regulating the consumption of alcohol, tobacco and processed foods. We ought to create surveillance systems to evaluate the impact of the agreement if it is signed, and generate mechanisms that prevent the little resources we already have devoted for health to be deviated to top technology that will not necessarily have a positive impact at a population level.
Type
info:eu-repo/semantics/articleRights
info:eu-repo/semantics/openAccessLanguage
spaISSN
1726-4642Collections
The following license files are associated with this item:
- Creative Commons
Related articles
- The Potential Impact of the Transatlantic Trade and Investment Partnership (TTIP) on public health.
- Authors: De Vogli R, Renzetti N
- Issue date: 2016 Mar-Apr
- Trans-Pacific Partnership Provisions in Intellectual Property, Transparency, and Investment Chapters Threaten Access to Medicines in the US and Elsewhere.
- Authors: Baker BK
- Issue date: 2016 Mar
- The NCI All Ireland Cancer Conference.
- Authors: Johnston PG, Daly PA, Liu E
- Issue date: 1999
- Global health and Brazilian foreign policy: the negotiations on innovation and intellectual property.
- Authors: Lima JHDS
- Issue date: 2017 Jul
- The Regional Comprehensive Economic Partnership, Intellectual Property Protection, and Access to Medicines.
- Authors: Townsend B, Gleeson D, Lopert R
- Issue date: 2016 Nov


